Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cbiotix LLC currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. The presence of 2 pending office actions across different administrative units suggests that the company is developing multiple distinct innovations or technical approaches within the Biotechnology & Pharmaceuticals field, necessitating a diversified response strategy.
The busiest examiner for this portfolio is KRUSE, DAVID H, who is responsible for 1 busiest examiner pending action. Since each of the 2 distinct examiners is handling one action, the prosecution workload is balanced. The involvement of 2 distinct art units means that the company must navigate different sets of examination guidelines while addressing the 2 pending office actions. Practitioners should focus on the specific feedback from KRUSE, DAVID H and the other assigned examiner to move these matters forward in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRUSE, DAVID H | 1 | 81.3% | +9.6% |
| BYRNES, DAVID R | 1 | 78.1% | +22.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18409352 | CANNABIS PLANT NAMED 'CK2015' | KRUSE, DAVID H | 66d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18409264 | CANNABIS PLANT NAMED 'BF2014' | BYRNES, DAVID R | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18409352 | CANNABIS PLANT NAMED 'CK2015' | KRUSE, DAVID H | 1663 | §103§112 | Final Rejection | 66d overdue | Pending | Jan 10, 2024 |
| 18409264 | CANNABIS PLANT NAMED 'BF2014' | BYRNES, DAVID R | 1662 | §103 | Final Rejection | — | Pending | Jan 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial